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Abstract: Purpose: To evaluate the efficacy of preoperative epoetin- on the revision hip arthroplasty patient. We 
hypothesized that epoetin- will reduce blood transfusion. A pertinent review of the literature is provided. 
Methods: Forty-six patients were retrospectively reviewed. Sixteen patients received epoetin-. Patients were case 
matched by age, preoperative hemoglobin, surgery, gender, and BMI. The clinical triggers for blood transfusion during or 
after the procedure were determined based on peri- and postoperative hemoglobin levels, ASA score, and/or clinical 
symptoms consistent with anemia. Blood salvage was not used. 
Results: Blood transfusion and length of stay were decreased in the epoetin- group. Hemoglobin in the intervention 
group increased from 12.0 to 14.5, preoperatively. Patients who received epoetin- were 0.78 (RR=0.225) times as likely 
to receive a transfusion. Number Needed to Treat (NNT) to avoid one allogeneic transfusion was 1.84. Age, Gender, BMI, 
ASA, total and hidden blood loss, preoperative Iron supplements, preop Hct, preop PLT, PT, PTT, and INR were similar. 
One (6.0%) patient developed an uncomplicated deep venous thrombosis in the intervention group. 
Conclusions: The mildly anemic revision hip arthroplasty patient is at increased risk for transfusion. Epoetin- increased 
preoperative hemoglobin counts and reduced transfusions in this study; it also decreased patient length of hospital stay 
likely allowing for an earlier readiness to resume normal activities and/or meet short-term milestones. A randomized study 
to evaluate the direct and indirect costs of such a treatment methodology in the mildly anemic revision patient may be 
warranted. 
Keywords: Anemia, orthopedic surgery, autologous blood donation, blood transfusion, epoetin-, revision total hip 
arthroplasty. 
INTRODUCTION 
 Revision hip arthroplasty is associated with increased 
transfusion needs [1]. A typical patient loses 4.0 g/dL, and 
receives three units [2] – such units have been of allogeneic 
or of autologous origin. However, both treatment modalities 
can lead to significant clinical morbidity. 
 Preoperative autologous donation has been used to 
prevent allogeneic transfusions. However, recent studies 
found that it may be less efficacious than anticipated. For 
instance, it can induce anemia, and thus may not be indicated 
when baseline hemoglobin levels (13.0 g/dl) are low [3]. In 
contrast, recent studies suggest that the primary hip 
arthroplasty patient may benefit from preoperative epoetin- 
more so than autologous donation [4]. Lastly, epoetin- was 
efficacious in numerous fields of medicine and surgery; one 
of which was orthopaedic trauma [5]. To the knowledge of  
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these authors, there has been one study that evaluated the use 
of preoperative epoetin- in the revision hip patient [6]. 
 The purpose of this study is to assess the effect of 
preoperative epoetin- injection on the mildly anemic patient 
- a population thought to hold a four-fold and fifteen-fold 
transfusion rate increase over those with levels between 
13.0-15.0g/dl and >15g/dl, respectively [7, 8]. Our 
hypothesis is that epoetin- injection will reduce 
transfusions. A pertinent review of the literature is provided. 
METHODS 
 Following Institutional Review Board (IRB) approval, 
we performed this retrospective analysis. Between January 
2007 and May 2010 there were 46 patients who met our 
inclusion and exclusion criteria. All of our patients received 
revision hip surgery for prosthesis wear out and/or 
loosening. All surgical procedures were elective. The 
following cases were excluded from the study: control 
subjects with pre-operative hemoglobin values less than 10 
g/dL or greater than 13g/dL, patients with hematological 
diseases or coagulation disorders, a prior history of deep  
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venous thrombosis or pulmonary embolus, and subjects who 
received a postoperative drain. We termed patients with a 
hemoglobin level at or below 13g/dL and at or above 10g/dL 
mildly anemic. 
 For initial hemoglobin levels (obtained a month prior to 
surgery) >13g/dL and 14g/dL, a pre-operative autologous 
collection was offered. When a hemoglobin level was 10 
and 13 g/dL, then three weekly doses of epoetin- were 
considered. All risks associated with epoetin- use were 
discussed. Patients that did not receive epoetin- treatment 
were patient matched according to age, gender, body mass 
index, and ASA score. All patients were offered oral multi-
vitamins, vitamin B12, folic acid, and iron. 
 The preoperative work-up, surgical technique, anesthesia, 
and postoperative management of patients in both groups 
were identical. All surgeries were completed under 
combined spinal-epidural anesthesia. A hardinge approach 
utilizing the old incision was performed on all patients. All 
THAs were non-cemented. Neither cell saver nor drains were 
used - at our institution, it is not a routine practice to utilize 
drains during THA without an indication. Through 4-weeks 
postop, proper anticoagulant (either oral warfarin or 
subcutaneous enoxaparin) was administered to the patient. 
The target INR for all patients was 2.0-2.5. The first dose of 
prophylactic antibiotic (1 gram IV cefazolin or vancomycin 
for allergic patients) was administered within one hour prior 
to incision and then continued for the first 24 hours after 
surgery. The clinical triggers for blood transfusion during or 
after the procedure were determined based on an 
intraoperative hemoglobin level 8, or symptoms consistent 
with anemia. 
 We used a chi-square test for the proportions of cases 
receiving blood, and Student’s t-test and Chi-square for 
comparing the continuous and categorical variables, 
respectively. For the statistical analysis, version 18 of 
PASW
®
 Statistics (SPSS Inc., an IBM Company 
Headquarters, Chicago, Illinois) was used. A p<0.05 was 
considered statistically significant. 
RESULTS 
 The demographic data for the two cohorts are reported in 
Table 1. The records of 46 patients were reviewed, and no 
difference was found in demographic data between cohorts 
for age, gender, ASA, or BMI. There were no differences in 
patient blood values for preoperative PT, PTT, INR, or 
platelet count (p>0.05). 
 The average postoperative total blood loss (TBL), hidden 
blood loss (HBL), and calculated blood loss (CBL) are 
provided in Table 2. The average estimated blood loss was 
lower in the group of patients receiving epoetin- (p=0.019). 
There was no difference in the median estimated blood loss. 
There was no difference in the average quantity of transfused 
blood. 
 The average use of 2.88 doses of epoetin- decreased the 
number of patients requiring transfusion. The discharge 
hemoglobin was higher in the intervention group. At the time 
of hospital admission the mean hemoglobin level was higher 
in the epoetin- group. The mean duration of surgery was 
similar for both cohorts. There was a shorter length of 
hospital stay for patients who received epoetin- (Table 2). 
Table 1. Demographic Data for Hip Revision Patients 
 
Characteristic Epoetin- Control p-Value 
Age (y) 70.7 74.1 0.349 
BMI (kg/m
2
) 28.8 26.8 0.249 
ASA score (no.) 2.56 2.70 0.404 
INR 1.33 1.39 0.966 
Platelet count (per mm
3
) 242,000 242,590 0.777 
Sg Duration (min) 79.2 92.0 0.145 
Length of Stay (days) 3.33 4.28 0.046 
 
 The index revision surgery was defined as any procedure 
in which at least acetabular, femoral, or liner/head 
components were exchanged. In the epoetin- cohort, 12 
(75%) patients had an acetabular revision. Three patients 
(18.8%) had a liner/head exchange, and 1 (6.3%) had a 
femoral component revision. In the control cohort, 21 (75%) 
of patients had an acetabular revision. Six patients had a 
liner/head exchange (21.4%), and 2 had a femoral revision 
(3.6%) (Table 3). 
 There was a single cardiovascular complication in this 
cohort. One of the patients in the intervention group 
(epoetin-) developed an uncomplicated deep venous 
thrombosis diagnosed by ultrasound. The patient was treated 
as an outpatient. No further complications were noted. 
 In the epoetin- group, 17.6% of the patients (3 of 17) 
required blood transfusion. This was significantly lower than 
the control group where 75.8% of the patients (22 of 29) 
received at least one unit of blood (p=0.0003) (Table 2). The 
relative risk of the epoetin- treatment regimen was 0.225 
(0.176/0.719). Number Needed to Treat (NNT) to avoid one 
allogeneic transfusion was 1.84 (1/(0.719-0.176)) (Table 2). 
DISCUSSION 
 While preoperative epoetin- injection has been shown to 
reduce peri- [9] and postoperative transfusions in primary 
hip replacements, there has been one report, to the 
knowledge of these authors, of its effect on the revision hip 
patient [6]. Our patients who received epoetin- were 
transfused less, had an elevated preoperative and discharge 
hemoglobin level, and a shorter hospital length of stay. 
Patients who received epoetin- were 0.78 (RR=0.225) times 
as likely to receive a transfusion. Number Needed to Treat 
(NNT) to avoid one allogeneic transfusion was 1.84. There 
was one blood-related study cohort complication of deep 
venous thrombosis (6.0%) in a patient that was not 
transfused. 
 Noordin et al. studied revision THA patients. They noted 
that the transfusion rate for epoetin- was no different than 
for a matched control group. However, not only did Noordin 
et al. use a different epoetin- drug regimen, dose schedule, 
and study inclusion criteria, but they also used a control 
cohort that consisted of emergent surgery for periprosthetic 
fractures or infections. Additionally, their study group 
patients had a lower ASA score as well as a decreased rate of 
comorbidities than their blood utilization program patients 
[6]. Our study differs because we patient-matched our 
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cohorts (age, BMI, gender, ASA) to decrease the inherent 
design flaws of a retrospective study. As such, we believe 
this study suggests that epoetin- may be an efficacious 
option to reduce blood transfusions in the revision hip 
arthroplasty patient [10, 11]. 
Table 3. Components for Hip Revision Study Patients 
 
Component Revisions 
Epoetin-  
(Total=16) 
Controls  
(Total=28) 
Acetabular  
revisions 
12 (75%) 
1 (8.3%) transfused 
21 (75%) 
19 (90%) transfused 
Femoral component  
revisions 
1 (6.3%) 
0 transfused 
1 (3.6%) 
0 transfused 
Liner/head  
exchange 
3 (18.8%) 
2 (66.7%) transfused 
6 (21.4%) 
1 (16.6%) transfused 
 
 Moonen et al. [4] conducted a randomized trial that 
compared two cohorts of 50 patients each with mild anemia 
(10Hb13g/dL) who underwent either primary total hip or 
knee arthroplasty. The group randomized to receive a 
preoperative epoetin- injection had a decreased blood 
transfusion frequency; however, the cost of the epoetin- 
intervention exceeded that of the autologous re-transfused 
blood group. Another randomized trial by Slappendel et al. 
[12] evaluated 695 patients with preoperative hemoglobin 
values of 10–13 g/dL who underwent elective orthopedic 
surgery – of which 113 patients had rheumatoid arthritis 
(RA). Their randomized cohorts consisted of either 
preoperative epoetin- injection with standard care or 
standard care alone. They concluded that RA patients 
benefitted from preoperative epoetin- treatment in 
combination with iron supplementation. 
 Gonzalez-Porras et al. [13] studied 305 patients who 
either underwent elective THA or TKA. The patients were 
individually assigned to one of five strategies: (1) no pre-
operative intervention; (2) oral iron therapy; (3) intravenous 
iron therapy; (4) recombinant human epoetin- with 
intravenous iron; and, (5) pre-operative autologous donation 
plus oral iron. They noted that preoperative autologous 
donation caused a reduction in hemoglobin levels. 
Furthermore, a multivariate subgroup analysis designed to 
evaluate postoperative transfusion risk factors determined 
that decreased weight and/or preoperative hemoglobin levels 
as well as the lack of a blood protocol strategy independently 
increased transfusion needs [13]. 
 Garvin et al. found blood loss was greater for revision 
THA femoral components than for acetabular in 147 patients 
[14]. Furthermore, Zarin et al. found that when femoral and 
acetabular components were revised together blood loss was 
highest; whereas either component revised alone had no 
difference [15]. Our study was not powered for such an 
analysis, but we identified for our controls that 90% of 
revised acetabular components required a transfusion, 
whereas for our study patients 8.3% of acetabular 
components required one. 
 Our study demonstrated that three weekly doses of 
40,000 units of epoetin- increased preoperative hemoglobin 
levels. Furthermore, for every 1.84 patients treated with 
epoetin-, we were able to prevent one transfusion. We also 
believe that epoetin- may be a more patient friendly and 
cost-effective treatment option for preoperative anemia [16]. 
For example, predonation of autologous blood can be an 
inefficient process since approximately 40-56% of it may be 
wasted [17, 18]. It also carries a risk for compartment 
syndrome, contamination, febrile and/or septic reactions, 
clerical error, and inflammatory processes [19]. Furthermore, 
it is known to induce a phlebotomy related anemia [3]. 
Therefore, we try to avoid its use. 
 Moonen et al. [4] reported that epoetin- injection, 
supplemented by ferrofumerate tablets, increased the cost per 
Table 2. Blood Data for Hip Revision Study Patients 
 
Characteristic Epoetin- Control p-value 
Average epoetin- dose 40,000u 2.88* 0 Na 
Epoetin- effect on Hb (g/dL) 12.0 to 14.5 Na 0.002 
Hb at Sg (g/dL) 14.0 12.0 <0.001 
Hb on discharge (g/dL) 10.1 9.39 0.016 
Transfusion (%) 17.6 71.9 <0.001 
Average transfusion (mL) 333 335 0.981 
Mean Total Blood Loss (mL) 1176 1047 0.424 
Mean Hidden Blood Loss (mL) 1065 1178 0.534 
Median Total Blood Loss (mL) 1118 1059 Na 
Median Hidden Blood Loss (mL) 1064 1145 Na 
Average transfused (mL) 333 335 0.981 
Mean Estimated Blood Loss (mL) 
189  
Range:50-500cc 
338 
Range:50-850cc 
0.019 
Median Estimated Blood Loss (mL) 150 200  
*Two of sixteen patients missed a preoperative dose for an unspecified reason. 
 Only pts with pre-injection CBC performed at our institution. 
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patient when compared with a re-transfusion system. Their 
result was based on a direct cost analysis in Euros. However, 
the scarcity of and risk associated with allogeneic blood, 
potential transfusion error, administrative cost of testing, 
storing, and transfusing blood also need to be considered in 
an analysis. Furthermore, length of stay and patient 
satisfaction, among others should be considered. We 
recommend pre-op iron, folic acid, vitamin B12, and 
multivitamin use to all our patients undergoing elective 
surgery. 
 According to Sehat KR et al, there may be hidden blood 
loss into the soft tissue and joint of an arthroplasty patient. 
We did not detect a difference, but our study was likely not 
powered to do so; however, our average total and hidden 
blood losses were elevated when compared to the primary 
THA patient [20]. Importantly, the total and hidden blood 
loss is not a perfect measure; a part of its flaw is that the 
estimated blood loss intra- and postoperatively is a 
subjective measure based off a non-standardized process. 
One study presented their results utilizing the median value 
for total and hidden blood loss due to the numerous outliers 
present [21]. Therefore, we found it difficult to compare our 
blood loss results to those published. However, one 
interesting finding derived from such calculations is that a 
total hip arthroplasty has a lower hidden blood loss than total 
knee arthroplasty [20]. The change in hemoglobin from pre- 
to postoperatively in our study cohort was 12 to 14.5g/dL. 
Such a change was similar to those recorded by Sehat KR et 
al. who noted that a THA without re-infusion had a change 
of 3.3 g/dL and 2.8 g/dL with re-infusion. These authors 
consider this to be clinically significant since postoperative 
hemoglobin levels have been shown to correlate with patient 
readiness to resume normal activities after elective 
arthroplasty. Furthermore, it is known that short-term 
milestones are reached more rapidly if patients participate in 
inpatient rehabilitation immediately after surgery [22]. 
 There is a thought that epoetin- may increase the 
occurrence of cardiovascular system side effects. However, 
there are also studies that link the drug with an anti-apoptotic 
activity that in preclinical and small clinical studies has been 
shown to protect cells from hypoxic and ischemic events 
[23-25]. It is possible that the anti-apoptotic activity of it 
may improve or prevent the outcome of an adverse event. 
However, cancer and chronic renal failure trial patients had 
an increased risk of thrombotic complications and death [26-
28]. Our protocol for epoetin- administration had one 
blood-related complication. One patient developed an 
uncomplicated deep venous thrombosis (6%). It is standard 
in our orthopedic practice to transfuse patients based on 
anemic symptoms, or a hemoglobin count less than 8. All 
patients received the same postoperative treatment course 
that consisted of anti-thromboprophylaxis, early ambulation, 
and physical therapy. Additionally, no study patient had an 
ischemic event. 
 There were limitations to our study. The patient 
enrollment in the epoetin- program was strictly voluntary, 
and the retrospective nature of our analysis invites the 
possibility of a confounding variable; however, we patient-
matched on age, gender, BMI, ASA score, and procedure. 
Also, our study patients, on average, used more supplements 
preoperatively. Therefore, it is possible that we captured the 
effect of not only epoetin- but also the vitamins; however, it 
is unlikely that the difference had a true clinical effect. 
Although estimated blood loss (EBL) was significantly 
different between our cohorts, we believe it was due to a few 
outliers present in the control group. Furthermore, the 
median estimated blood loss in the study and control groups 
were 150 and 200ml, respectively. Our series included a 
consecutive group of patients that received epoetin-. 
Additionally, spinal anesthesia is thought to decrease 
perioperative loss when compared to general anesthesia [29]. 
Most of our patients underwent spinal anesthesia, but a few 
required general. Also, we did not include patients with a 
prior thromboembolic history because they are inherently at 
increased risk of clotting. Lastly, the trigger for transfusions 
is generally physician dependent. To account for this, we 
included cases performed by two surgeons only who have 
similar transfusion triggers as stated previously. 
 In conclusion, the present study demonstrates that the 
mildly anemic revision hip arthroplasty patient is at 
increased risk for transfusion. It also may suggest that 
epoetin- could decrease the need for blood transfusion 
and/or decrease the length of hospital stay for the mildly 
anemic patient allowing earlier return to normal activities 
and/or to meet short-term milestones [22]. A randomized 
study to evaluate the direct and indirect costs of such a 
treatment methodology in the mildly anemic revision hip 
patient may be warranted. 
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